Komori
Ube (4208) · RiskRestated

Improper Practices in Quality Inspections

First written in FY2018. 2 of 3 entries say "Materialised", first in FY2018. Latest entry: FY2021.

3entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2018 – FY20192018: 120182019: 120192020: 020202021: 12021
Same theme, other companies
Damage to Quality and Trust Caused by Improper Inspection of Products and ServicesA theme 3 companies write about · 3 as a headwind · 0 as a tailwind

Ube moved to the "Worse" side of this theme in 2018.

2 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Moved together

"Approval, commercialization and R&D risks in the active pharmaceutical ingredient and intermediate business" moved the same way as this thread, in the same document, in 2 of its 3 moves.

22★12
  1. ★This thread
  2. 1Approval, commercialization and R&D risks in the active pharmaceutical ingredient and intermediate business2×
  3. 2Exit from underperforming businesses and review of assets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ube's next results are scheduled for 2026-11-05. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.